Praecis Jumps 150% on Glaxo Buyout Offer
by H.S. Ayoub
BioHealthInvestor.com
Shares of Praecis Pharmaceuticals (PRCS) jumped more than 140% in pre-market action on Thursday after GlaxoSmithKline (GSK) made an offer to buy the majority of outstanding common stock of the little biotech for $54.8 million, or $5 a share.
Praecis closed trading on Wednesday at $2 a share.
Key to the buyout is Praecis's DirectSelect platform technology which allows for use of ultra-large libraries for the discovery of orally active compounds for drug development. The Molecular Discovery Research unit of GSK is very interested in this platform, as it could complement its own drug discovery research.
Praecis also has PPI-2458 in clinical development for cancer indications, including non-Hodgkin's lymphoma and solid tumors.
Praecis lost over $61 million in fiscal 2005, and has a total worth of $20 million on the market.
And with only about $40 million in cash Praecis needed this deal much more than GSK.
__________
Related BHI articles:
- GlaxoSmithKline May Benetif from Weak U.S. Dollar
- GSK Vaccine Could Cut Cervical Cancer by 80%
__________
BioHealthInvestor.com
Shares of Praecis Pharmaceuticals (PRCS) jumped more than 140% in pre-market action on Thursday after GlaxoSmithKline (GSK) made an offer to buy the majority of outstanding common stock of the little biotech for $54.8 million, or $5 a share.
Praecis closed trading on Wednesday at $2 a share.
Key to the buyout is Praecis's DirectSelect platform technology which allows for use of ultra-large libraries for the discovery of orally active compounds for drug development. The Molecular Discovery Research unit of GSK is very interested in this platform, as it could complement its own drug discovery research.
Praecis also has PPI-2458 in clinical development for cancer indications, including non-Hodgkin's lymphoma and solid tumors.
Praecis lost over $61 million in fiscal 2005, and has a total worth of $20 million on the market.
And with only about $40 million in cash Praecis needed this deal much more than GSK.
__________
Related BHI articles:
- GlaxoSmithKline May Benetif from Weak U.S. Dollar
- GSK Vaccine Could Cut Cervical Cancer by 80%
__________
posted by Nico at
8:57 AM
4 Comments:
FYI Glaxo paid about $15m for their products. PRCS has approx. cash of $40m.
My apologies,
I meant about 4 per share, or $40 million in total.
Thanks for pointing the error out.
No worries mate. Just wondering why you thought PRCS needed the deal if they had that much cash on hand? They still had some development stage compounds.
the company had a cash flow of -$25 million last year, so the $40 million is not enough, unless they dilute their stock value through issueing more shares.
Post a Comment
Subscribe to Post Comments [Atom]
<< Home